TSX runs higher on rate cut expectations
Investing.com - UBS maintained its Neutral rating and $595.00 price target on Regeneron Pharmaceuticals (NASDAQ:REGN), currently trading at $594.55, following positive Phase 3 trial results for its experimental myasthenia gravis treatment. The $60.8 billion biotech company maintains a "GREAT" financial health score according to InvestingPro analysis.
The Phase 3 NIMBLE trial evaluated cemdisiran, a C5 siRNA therapy, in patients with symptomatic, AChR-positive generalized myasthenia gravis (gMG). The monotherapy arm using cemdisiran 600mg every 12 weeks demonstrated statistically significant improvements compared to placebo.
The trial showed placebo-adjusted changes of -2.30 in MG-ADL and -2.77 in QMG scores, which UBS noted were higher than what competitor C5 inhibitor Ultomiris has achieved at similar timepoints. Additionally, 76.6% of patients achieved a greater than 3-point reduction in MG-ADL scores.
The combination therapy arm using cemdisiran 200mg with pozelimab 200mg every 4 weeks showed less improvement, with changes of -1.74 in MG-ADL and -1.86 in QMG scores. On the safety front, no meningococcal infections were reported, and treatment-emergent adverse events were well balanced across treatment groups.
Regeneron plans to submit cemdisiran to the FDA in the first quarter of 2026, with full data from the NIMBLE study expected to be presented at an upcoming medical conference. With 11 analysts recently revising earnings estimates upward, InvestingPro subscribers can access detailed analysis and 8 additional key insights about Regeneron’s financial outlook in the comprehensive Pro Research Report.
In other recent news, Regeneron Pharmaceuticals has been at the center of several notable developments. The company announced that its investigational drug cemdisiran met primary and key secondary endpoints in a Phase 3 trial for adults with generalized myasthenia gravis (gMG). This promising result from the NIMBLE trial has led Jefferies to raise its price target for Regeneron to $831, maintaining a Buy rating on the stock. Similarly, Bernstein increased its price target to $781, citing positive trial data and adding the potential treatment to its financial model, which increased future earnings per share estimates by 7%.
Rothschild Redburn initiated coverage on Regeneron with a Buy rating and set a price target of $890, based on a valuation methodology that combines discounted cash flow and net present value approaches. TD Cowen maintained its Buy rating and a $780 price target, expressing confidence in Regeneron’s pipeline, particularly in the allergy programs and long-term bispecific antibody opportunities. These recent analyses highlight the growing optimism among analysts regarding Regeneron’s potential in both its current and future projects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.